Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 Mai 2023 - 4:30PM
Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company
developing a portfolio of oral integrin therapies for the treatment
of serious chronic diseases, today announced the closing of an
underwritten public offering of 6,133,334 shares of its common
stock at a price to the public of $45.00 per share, which includes
800,000 shares sold upon full exercise of the underwriters’ option
to purchase additional shares of common stock. Morphic received
gross proceeds of approximately $276.0 million, before deducting
underwriting discounts and commissions and other estimated offering
expenses.
Jefferies, TD Cowen, BMO Capital Markets, RBC Capital Markets
and Wells Fargo Securities acted as joint book-runners for the
offering.
The shares are being offered by Morphic pursuant to a
registration statement on Form S-3ASR previously filed with the
Securities and Exchange Commission (the “SEC”), which became
automatically effective upon filing. A preliminary prospectus
supplement and accompanying prospectus relating to this offering
have been filed with the SEC. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to this
offering, and when available, the final prospectus supplement, may
be obtained from: Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, New York, NY 10022, by
telephone at 877-547-6340 or by email at
Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or BMO
Capital Markets Corp. at 151 W 42nd Street, 32nd Floor, New York,
NY 10036, Attention: Equity Syndicate Department, by telephone at
(800) 414-3627 or by email to bmoprospectus@bmo.com; or RBC Capital
Markets, Attention: Equity Capital Markets, 200 Vesey Street, 8th
Floor, New York, NY 10281, or by telephone at (877) 822-4089 or by
email at equityprospectus@rbccm.com; or Wells Fargo Securities,
LLC, Attention Equity Syndicate Department, 500 West 33rd Street,
New York, NY 10001, by telephone at (833) 690-2713, or by email at
cmclientsupport@wellsfargo.com. Electronic copies of the
preliminary prospectus supplement and accompanying prospectus will
also be available on the website of the SEC at
http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of Morphic, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a
portfolio of oral integrin therapies for the treatment of serious
chronic diseases, including autoimmune, cardiovascular, and
metabolic diseases, fibrosis, and cancer. Morphic is advancing its
pipeline and discovery activities using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology.
ContactsMorphic TherapeuticChris
Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Morphic (NASDAQ:MORF)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024